BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON(BRNS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BRNS BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON

Trading 12-16 09:57:18 EST

0.7400

+0.0000

0.00%

High0.7400	Low0.7400	Vol2.45K
Open0.7400	D1 Closing0.7400	Amplitude0.00%
Mkt Cap30.21M	Tradable Cap26.40M	Total Shares40.83M
T/O1.83K	T/O Rate0.01%	Tradable Shares35.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BRNS","market":"US","secType":"STK","nameCN":"BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON","latestPrice":0.74,"timestamp":1765896769800,"preClose":0.74,"halted":0,"volume":2445,"delay":0,"floatShares":35677165,"shares":40830353,"eps":-1.880153,"marketStatus":"Trading","change":0,"latestTime":"12-16 09:57:18 EST","open":0.74,"high":0.74,"low":0.74,"amount":1828.99166325,"amplitude":0,"askPrice":0.7499,"askSize":100,"bidPrice":0.7216,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.880153,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765918800000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1619755200000,"exchange":"NASDAQ","adjPreClose":0.74,"postHourTrading":{"tag":"盘后","latestPrice":0.74,"preClose":0.74,"latestTime":"18:32 EST","volume":114,"amount":82.9653,"timestamp":1765841551113},"volumeRatio":0.271794},"requestUrl":"/m/hq/s/BRNS/tweets","defaultTab":"tweets","newsList":[{"id":"2590385587","title":"Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2590385587","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590385587?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:00","pubTimestamp":1765371600,"startTime":"0","endTime":"0","summary":"VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000 was well-tolerated with no treatment-related","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203120/0/en/Barinthus-Bio-Announces-Update-on-Phase-1-AVALON-Clinical-Trial-of-VTP-1000-for-the-Treatment-of-Celiac-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTP","BK4539","BRNS","BK4139"],"gpt_icon":0},{"id":"2584236916","title":"Barinthus Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2584236916","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584236916?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:39","pubTimestamp":1763383140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BRNS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 07:39 ET (12:39 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BRNS"],"gpt_icon":0},{"id":"2581000427","title":"Barinthus Biotherapeutics Q3 EPS $(0.36) Beats $(0.45) Estimate, Sales $14.969M, Same YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000427","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000427?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:41","pubTimestamp":1762519310,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics Q3 EPS $(0.36) Beats $(0.45) Estimate, Sales $14.969M, Same YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48716523/barinthus-biotherapeutics-q3-eps-0-36-beats-0-45-estimate-sales-14-969m-same-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS","BK4539","BK4139"],"gpt_icon":0},{"id":"2581005130","title":"Press Release: Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2581005130","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581005130?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:30","pubTimestamp":1762518600,"startTime":"0","endTime":"0","summary":"-- Single ascending dose data readout for VTP-1000 expected before the end. -- Enrollment advancing in multiple ascending dose part of the AVALON trial;-- Proposed combination with Clywedog Therapeutics Inc.  to. strengthen and diversify the pipeline and broaden the Company's base of. GERMANTOWN, Md., Nov. 07, 2025  -- Barinthus Biotherapeutics plc  , an immunology and inflammation  company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial results for the quarter ended September 30, 2025, and provided an overview of the Company's corporate developments.\"The proposed combination of Barinthus Bio and Clywedog represents an important step toward building a stronger, more resilient company, with several expected near-term catalysts.\" said Bill Enright, Chief Executive Officer of Barinthus Bio. \"By combining our complementary pipelines and deep expertise in metabolic and autoimmune diseases, we are diversifying risk across m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS","BK4539","BK4139"],"gpt_icon":0},{"id":"2579938484","title":"Barinthus Biotherapeutics PLC  expected to post a loss of 45 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2579938484","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579938484?lang=en_us&edition=fundamental","pubTime":"2025-10-31 22:26","pubTimestamp":1761920767,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics PLC  expected to post a loss of45cents a share - Earnings Preview Barinthus Biotherapeutics PLC BRNS.OQ, BRNS.O is expected to  show a fall in quarterly revenue when it repor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC1ME:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRNS","BK4539"],"gpt_icon":0},{"id":"2577485285","title":"Press Release: ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2577485285","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577485285?lang=en_us&edition=fundamental","pubTime":"2025-10-24 23:00","pubTimestamp":1761318000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company enters into a definitive merger agreement with Barinthus Therapeutics . The combined entity will operate under the name Clywedog Therapeutics, Inc. and is expected to list on Nasdaq under the ticker CLYD upon closing. The merged portfolio will focus on advancing clinical-stage candidates in Type 1 diabetes , Type 2 diabetes , and celiac disease.ChemDiv's ongoing collaboration includes accelerated CMC research, AI-enabled pharmacology, computational modeling, and translational biology, extending the successful transition of Clywedog's programs to the clinic in 2023--2024. ChemDiv's medicinal chemistry, in vitro and in vivo biology, and pharmacology services were instrumental in differentiating:. MEN PPI inhibitors -- first-in-class can","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4539","BRNS","LENZ"],"gpt_icon":0},{"id":"2571342908","title":"Press Release: Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2571342908","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571342908?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:00","pubTimestamp":1759233600,"startTime":"0","endTime":"0","summary":"includes three differentiated, clinical stage product candidates which. -- Four key value-driving milestones are expected within 18 months,including clinical proof of concept in multiple indications. Estimated. cash runway for combined company extends through 2027.-- Transaction projected to close in the first half of 2026. The combined. company will be backed by OrbiMed and Torrey Pines and is expected to. Upon the closing of the transaction, the combined company will be renamed \"Clywedog Therapeutics, Inc.\" and is expected to trade on the NASDAQ under the new ticker symbol \"CLYD.\" The transaction is expected to close in the first half of 2026, with the combined company supported by existing cash and additional investments by OrbiMed and Torrey Pines Investment LLC, both existing shareholders in Clywedog, and new investors.Dr. Iain Dukes, a venture partner at OrbiMed who will serve as Executive Chairman of Clywedog Therapeutics after the transaction closes, commented, \"I am excited to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NQmain","BK4139",".IXIC","MNQmain","BK4539","PSQ","NVIW.SI","TQQQ","USJW.SI","QLD","TSYW.SI","SQQQ","LENZ","BRNS","USAW.SI","QID"],"gpt_icon":1},{"id":"2557986165","title":"Barinthus Biotherapeutics PLC reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2557986165","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557986165?lang=en_us&edition=fundamental","pubTime":"2025-08-08 01:32","pubTimestamp":1754587977,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics PLC reports results for the quarter ended June 30 - Earnings SummaryBarinthus Biotherapeutics PLC BRNS.OQ reported a quarterly adjusted loss of 52 cents per share for the qua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nL8N3TZ2RV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2557456872","title":"Barinthus Biotherapeutics Q2 EPS $(0.52) Misses $(0.33) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557456872","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557456872?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:12","pubTimestamp":1754568776,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.33) by 57.58 percent. This is a 20.93 percent decrease over losses of $(0.43) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46959532/barinthus-biotherapeutics-q2-eps-0-52-misses-0-33-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2557565472","title":"Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2557565472","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557565472?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:00","pubTimestamp":1754568000,"startTime":"0","endTime":"0","summary":"The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025;The multiple ascending dose (MAD)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129180/0/en/Barinthus-Bio-Reports-Second-Quarter-2025-Financial-Results-and-Updates-on-Corporate-Developments.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS","BK4539","BK4139"],"gpt_icon":0},{"id":"2556038732","title":"Barinthus Biotherapeutics PLC  expected to post a loss of 33 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2556038732","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556038732?lang=en_us&edition=fundamental","pubTime":"2025-08-04 21:54","pubTimestamp":1754315647,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics PLC  expected to post a loss of33cents a share - Earnings Preview Barinthus Biotherapeutics PLC BRNS.OQ, BRNS.O is expected to  show no change in quarterly revenue when it re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nL8N3TW1EK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.barinthusbio.com","stockEarnings":[{"period":"1week","weight":0.0529},{"period":"1month","weight":-0.0692},{"period":"3month","weight":-0.2952},{"period":"6month","weight":-0.1494},{"period":"1year","weight":-0.189},{"period":"ytd","weight":-0.3874}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.0787},{"month":2,"riseRate":0.25,"avgChangeRate":-0.075991},{"month":3,"riseRate":0,"avgChangeRate":-0.162289},{"month":4,"riseRate":0.75,"avgChangeRate":0.019565},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038691},{"month":6,"riseRate":0.4,"avgChangeRate":-0.079301},{"month":7,"riseRate":0.8,"avgChangeRate":0.145921},{"month":8,"riseRate":0.2,"avgChangeRate":-0.115362},{"month":9,"riseRate":0.6,"avgChangeRate":0.076316},{"month":10,"riseRate":0.6,"avgChangeRate":0.081459},{"month":11,"riseRate":0,"avgChangeRate":-0.272926},{"month":12,"riseRate":0.6,"avgChangeRate":0.082579}],"exchange":"NASDAQ","name":"BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON","nameEN":"BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON(BRNS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON(BRNS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON,BRNS,BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON股票,BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON股票老虎,BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON股票老虎国际,BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON行情,BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON股票行情,BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON股价,BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON股市,BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON股票价格,BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON股票交易,BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON股票购买,BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON(BRNS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON(BRNS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction